Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Neural Stem Cell Stories

2013-05-28 08:29:50

ROCKVILLE, Md., May 28, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper published today in the journal, STEM CELL RESEARCH AND THERAPY http://stemcellres.com/, showed that rats transplanted with its spinal cord-derived human neural stem cells, NSI-566, three days after a spinal cord injury at L3 (lumbar 3), showed improvement along several measures of motor function and a reduction of spasticity. The study, "Amelioration of Motor/Sensory Dysfunction and Spasticity...

2013-05-16 23:22:54

In a study just published in STEM CELLS Translational Medicine, researchers have found a new way to increase the survival of stem cells injected into the brain. The discovery might one day prove useful in developing new treatments for neurological disorders – especially brain lesions, which among other things can provoke seizures and indicate multiple sclerosis or certain forms of cancer. Durham, NC (PRWEB) May 16, 2013 Researchers have found a new way to increase the survival of stem...

2013-05-16 08:29:29

ROCKVILLE, Md., May 16, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, will present at the Annual World Stem Cells and Regenerative Medicine Congress on Thursday, May 23, in London, UK. Mr. Garr's talk, "Understanding the Practicalities of Using Innovative Therapies on Patients," at 2:05 PM, will explore how cell therapies will be used by clinicians and integrated into hospital settings...

2013-05-15 23:02:15

Decreasing the amount of oxygen traditionally used when culturing stem cells for use in neurological therapies could drastically affect their survival rate. In fact, it could double it, according to a new study released today in STEM CELLS Translational Medicine. Durham, NC (PRWEB) May 15, 2013 Decreasing the amount of oxygen traditionally used when culturing stem cells for use in neurological therapies could drastically affect their survival rate. In fact, it could double it, according to...

2013-05-10 16:24:50

ROCKVILLE, Md., May 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2013 and provided a business and clinical update. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "The Company continues to progress all of its clinical trial programs, in the U.S. and abroad, as we move into 2013. The FDA has approved our Phase II trial protocol for NSI-566/ALS, which we expect to initiate this summer. The...

2013-05-09 11:22:27

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity. "We think this one type of cell may be useful in treating several types of neurodevelopmental and...

2013-05-08 08:28:59

Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial ROCKVILLE, Md., May 8, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will be a guest on Sirius XM's Doctor Radio station, channel 81, on Thursday, May 9, 10-11am EDT. Dr. Feldman will be on...

2013-04-22 08:30:20

ROCKVILLE, Md., April 22, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). NSI-189, the lead compound in Neuralstem's neurogenic small molecule platform, is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus, a...

2013-03-14 08:29:23

ROCKVILLE, Md., March 14, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, was listed as the 15(th) most influential person in the stem field in the "Top 50 Global Stem Cell Influencers," published by Total BioPharma, a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The list is the result of a global stem cell...

2013-02-20 08:29:53

ROCKVILLE, Md., Feb. 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center the non-exclusive right to use the licensed intellectual property in...